Skye Bioscience, Inc. (SKYE)

$0.01815

-0.00 (-1.89%)
Rating:
Recommendation:
-
Symbol SKYE
Price $0.01815
Beta 0.539
Volume Avg. 0.67M
Market Cap 16.556M
Shares () -
52 Week Range 0.011-0.069
1y Target Est -
DCF Unlevered SKYE DCF ->
DCF Levered SKYE LDCF ->
ROE -614217.38% Strong Sell
ROA -297186.98% Strong Sell
Operating Margin -
Debt / Equity -187.33% Sell
P/E -0.82
P/B -2.74 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest SKYE news


Healthcare
Biotechnology
Other OTC

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.